Loading

wait a moment

Tag: lung carcinoma

Treatment of Stage IIIA Non-small Cell Lung CancerPotentially Resectable N2 Disease

6. Induction (Neoadjuvant) Therapy: Patients with stage IIIA (N2) lung cancer identified preoperatively have a relatively poor prognosis when treated with surgery as a single modality. Several small trials of induction chemotherapy have yielded conflicting results about its effect on Read More

Treatment of Stage IIIA Non-small Cell Lung Cancer: Summary of Recommendations

Despite many earlier studies, the optimal treatment recommendations in the various clinical presentations of stage IIIA (N2) disease are unclear. Hopefully, as the current phase III trials accrue and mature and the much-needed, subsequent randomized trials with newer chemotherapy agents Read More

Treatment of Stage IIIA Non-small Cell Lung Cancer: Combination Chemotherapy and Radiotherapy

B. Neoadjvuant (Induction) Therapy Phase III Randomized Trials in Resectable Stage IIIA North American Intergroup 0139: This trial compares concurrent combination chemotherapy with cisplatin and etoposide plus radiotherapy followed by surgery or radiotherapy in stage IIIA (N2) disease (completed accrual Read More

Treatment of Stage IIIA Non-small Cell Lung Cancer: Ongoing Clinical Trials

Perhaps the greatest challenge to the clinician in the optimal management of stage IIIA disease is the lack of meaningful, definitive data from large randomized trials on which to base treatment decisions. A large number of phase I and II Read More

Treatment of Stage IIIA Non-small Cell Lung Cancer: unresectable IIIA (N2) disease

Newer-generation chemotherapeutic agents, alone or in combination with the platinum agents, are being incorporated into combined modality chemotherapy plus radiotherapy for locally advanced disease. As an example, a recent phase II trial in locally advanced disease used induction paclitaxel with Read More

Treatment of Stage IIIA Non-small Cell Lung Cancer: Chemotherapy plus radiotherapy

Concurrent Chemotherapy and Radiotherapy: Concurrent chemotherapy with radiotherapy has been studied in the locally advanced setting through randomized trials that have attempted to capitalize on the radiosensitizing properties of chemotherapy. An EORTC three-arm trial published in 1992 compared radiotherapy (split Read More

Treatment of Stage IIIA Non-small Cell Lung Cancer: PS-2 patients

The superiority of combined-modality chemotherapy plus radiotherapy in a sequential fashion compared to radiotherapy alone has been shown in several other large randomized trials including a Radiation Therapy Oncology Group trial showing an improved 1-year and median survival with chemotherapy Read More

Treatment of Stage IIIA Non-small Cell Lung Cancer: CALGB

In general, trials using platinum-containing chemotherapy regimens in combination with radiotherapy have shown good tumor response rates and have suggested an improvement in survival. One promising pilot trial showed significantly improved median and 2-year survivals of 16 months and 30%, Read More

Treatment of Stage IIIA Non-small Cell Lung Cancer: ECOG

A recent Eastern Cooperative Oncology Group (ECOG) pilot study (ECOG 4593) utilized this schedule and obtained a preliminary median survival of 13 months with acceptable toxicities, primarily esophagitis, at the completion of radiother-apy. In a subsequent companion quality-of-life assessment of Read More

Treatment of Stage IIIA Non-small Cell Lung Cancer: CHART

Radiotherapy Alone: Early attempts to use non-surgical treatment modalities for unresectable locally advanced disease (our stage IIIA4) involved single modality chest radiotherapy, yielding poor survivals at 5 years of 5 to 10% with traditional dose and fractionation schedules (1.8 to Read More

Pages: 1 2 3 4 Next